U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. AURA3: Abdominal pain
  1. Section N/A

AURA3: Abdominal pain

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 25KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, how OFTEN did you have PAIN IN THE ABDOMEN (BELLY AREA)?"

Patients scored the frequency of their Abdominal Pain on a 5-point scale (Never, Rarely, Occasionally, Frequently, Almost Constantly)

Patient-Reported Abdominal Pain During the First 24 Weeks on Treatment for Patients Who Completed a Questionnaire:

Figure 1 shows the percentage of patients reporting how often they had Abdominal Pain at each time point. For example, at week 2, 27% of patients taking Tagrisso reported Abdominal Pain (ranging from Rarely to Frequently). The range of patients who had any Abdominal Pain during the first 24 weeks of treatment with Tagrisso was between 22% - 41%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Abdominal Pain During the First 24 Weeks on Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, showing proportion of patients reporting the frequency of abdominal pain at each time point through the first 24 weeks of treatment. For example, at week 2, 27% of patients taking Tagrisso reported abdominal pain (ranging from Rarely to Frequently).

All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Abdominal Pain That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Abdominal Pain During the First 24 Weeks on Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, summarizing the percentage of patients by worst reported abdominal pain during the first 24 weeks of the clinical trial. In the Tagrisso arm, Never (32%), Rarely (25%), Occasionally (32%), Frequently (9%) and Almost constantly (2%). In the chemotherapy arm, Never (24%), Rarely (20%), Occasionally (33%), Frequently (18%) and Almost constantly (5%).

Patients with at least one on-treatment Abdominal Pain score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Abdominal Pain Before Treatment:

For patients that did not report Abdominal Pain before treatment, Figure 3 shows the percentage of patients reporting how often they had Abdominal Pain between weeks 1 and 24.

Figure 3. Patient-Reported Abdominal Pain During the First 24 Weeks on Treatment: Patients Without Abdominal Pain Before Treatment

Two stacked bar charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no abdominal pain before treatment. The bar charts show the proportion of patients reporting frequency of abdominal pain at each time point through 24 weeks. For example, at week 2, 15% of patients taking Tagrisso reported abdominal pain (ranging from Rarely to Occasionally).

All responses from patients who did not report Abdominal Pain before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Abdominal Pain That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Abdominal Pain Before Treatment:

Figure 4. Worst Patient-Reported Abdominal Pain During the First 24 Weeks on Treatment: Patients Without Abdominal Pain Before Treatment

Two pie charts, one for Tagrisso and the other for chemotherapy, which includes only those patients who had no abdominal pain before treatment. The pie charts summarize the percentage of patients by worst reported abdominal pain. In the Tagrisso arm, Never (40%), Rarely (26%), Occasionally (32%), Frequently (2%) and Almost constantly (0%). In the chemotherapy arm, Never (32%), Rarely (28%), Occasionally (28%), Frequently (12%), and Almost constantly (0%).

Patients who had no Abdominal Pain before treatment and at least one on-treatment Abdominal Pain score were included in the analysis. Tagrisso (N=65), Chemotherapy (N=25).

Back to Top